Dr. Butler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1660 Spring Hill Ave
Mobile, AL 36604Phone+1 251-665-8000Fax+1 251-665-8010
Summary
- Dr. Thomas Butler is an oncologist in Mobile, AL and is affiliated with multiple hospitals in the area, including Mobile Infirmary Medical Center, University of South Alabama Children's and Women's Hospital, USA Health University Hospital, and Thomas Hospital. He received his medical degree from the University of Tennessee College of Medicine and has been in practice for 36 years. He specializes in supportive oncology and palliative care as well as hematology.
Dr. Thomas W. Butler is a Hematologist and Medical Oncologist, specializing in Palliative Care and Cancer Related Fatigue. He completed a Hematology and Medical Oncology Fellowship at the University of Alabama at Birmingham.
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988- University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1986
University of Tennessee College of Medicine at ChattanoogaResidency, Internal Medicine, 1981 - 1984
University of Tennessee Health Science Center College of MedicineClass of 1981
Certifications & Licensure
TN State Medical License 1981 - 2026
AL State Medical License 1984 - 2024
NC State Medical License 1989 - 2008
TX State Medical License 1988 - 1991- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
- Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Publications & Presentations
PubMed
- 77 citationsImplementation and Impact of Patient Lay Navigator-Led Advance Care Planning Conversations.Gabrielle B. Rocque, J. Nicholas Dionne-Odom, Chao-Hui Sylvia Huang, Soumya J. Niranjan, Courtney P. Williams
Journal of Pain and Symptom Management. 2017-04-01 - 39 citationsSON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated GenesJung-Hyun Kim, Melody Baddoo, Eun Young Park, Joshua K. Stone, Hyeonsoo Park
Molecular Cell. 2016-03-17 - 13 citationsComplexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (C...Nikolaos Tsoukalas, Norman Brito-Dellan, Carme Font, Taylor Butler, Cristhiam M Rojas-Hernandez
Supportive Care in Cancer. 2022-10-01
Professional Memberships
- Member
- Member
- Multinational Association of Supportive Care In CancerMember
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
